Given the lack of successive treatment lines, new strategies are emerging, such as the combination of anti-PD1 and anti-EGFR agents.<h4>Materials and methods</h4>We conducted a retrospective, monocentric cohort study including patients treated in our oncodermatology department between 2013 and 2024 for advanced cSCC refractory to anti-PD1 monotherapy and who received a combination of anti-PD1 and anti-EGFR as second- or third-line therapy. This evidence concerns the gene EGFR and skin squamous cell carcinoma.